Latest Administration News

HomeCo Daily Needs REIT has announced a quarterly distribution of 2.125 cents per unit for the period ending March 31, 2025, reaffirming its commitment to delivering steady income to investors.

Clarity Pharmaceuticals has initiated its second registrational Phase III AMPLIFY trial for the Cu-SAR-bisPSMA PET imaging agent targeting biochemical recurrence of prostate cancer. The multi-centre study aims to generate critical data supporting FDA approval and could redefine prostate cancer diagnostics.

Atomo Diagnostics Limited has announced a capital raising initiative comprising a Share Purchase Plan (SPP) and a Placement, aiming to raise up to $1 million through the SPP and additional funds via a Placement, subject to shareholder approval at a June 23 meeting.

Avecho Biotechnology has expanded its pivotal Phase III clinical trial for a CBD insomnia treatment by adding new recruitment sites and partnering with pharmaceutical giant Sandoz to boost patient enrolment and regulatory progress.

LTR Pharma has expanded patient access to its fast-acting erectile dysfunction treatment SPONTAN by partnering with TerryWhite Chemmart’s extensive pharmacy network, marking a significant step in its commercial rollout and regulatory strategy.

Lumos Diagnostics has secured Medicare reimbursement for its FebriDx test from a fifth contractor, covering more than 70% of US Medicare payments and advancing its commercial reach.

State Street Global Advisors announces key updates to its SPDR Fixed Income ETFs, including a significant fee reduction for the Australian Bond ETF and a rebranding to incorporate the iBoxx index name, effective June 2025.

Anson Resources has negotiated a pioneering scaled royalty structure for its Green River Lithium Project in Utah, reducing the previous flat 5% rate to a sliding scale tied to lithium prices. This move enhances project viability and investment certainty amid evolving regulatory reforms.

Almonty Industries reports steady tungsten market conditions and completes key financing for its Sangdong Mine, while posting a $34.6 million net loss in Q1 2025. The company advances its US Domestication and plans to restart Los Santos Mine in 2026.

Cynata Therapeutics confirms that the recent FDA orphan-drug exclusivity granted to Ryoncil® will not block approval of its CYP-001 therapy, highlighting key differences in drug composition and patient indications.

Field Solutions Group has executed a binding agreement to sell its TasmaNet business to Comms Group Ltd as part of its receivership process, with further asset sales underway.

The Finnish Government’s proposed amendments to the Mining Act could resolve licensing uncertainties for Latitude 66’s KSB Project, even as key mining rights expire following a court decision.